Immunology and Microbiology
Cyclophosphamide
100%
Graft-Versus-Host Disease
83%
Multiple Myeloma
53%
Transplant Procedure
46%
Bone Marrow Transplantation
46%
Drug Megadose
40%
Overall Survival
34%
Conditioning
30%
Progression Free Survival
23%
Acute Graft Versus Host Disease
23%
T Cell
21%
Chronic Graft Versus Host Disease
20%
Recurrence Free Survival
18%
Myeloid
17%
Allogeneic Bone Marrow Transplantation
15%
Lymphocyte
15%
Lenalidomide
14%
Allotransplantation
12%
Aplastic Anemia
10%
Immunosuppression
9%
Allotransplantation
8%
Event Free Survival
8%
Cancer Stem Cell
8%
Myeloma Cell
7%
Tacrolimus
7%
Peripheral Blood Stem Cell Transplantation
7%
Dexamethasone
7%
Vaccine Efficacy
7%
Peptoclostridium difficile
7%
Granulocyte Macrophage Colony-Stimulating Factor
7%
Survival Rate
6%
Immunosuppressive Therapy
6%
Stem Cell
6%
Plasma Cell
6%
B Cell
5%
Cytokine Release Syndrome
5%
Immunosuppressive Drug
5%
Chimera
5%
Keyphrases
Post-transplantation Cyclophosphamide (PTCy)
67%
Multiple Myeloma
63%
Graft-versus-host Disease (GvHD)
55%
Confidence Interval
28%
Nonmyeloablative
24%
Haploidentical Transplantation
23%
HLA-haploidentical
21%
NCCN Guidelines
20%
Graft-versus-host Disease Prophylaxis
18%
Allogeneic Blood or Marrow Transplantation
18%
Overall Survival
18%
Allogeneic Bone Marrow Transplantation
17%
High Dose
17%
HLA Matching
16%
Transplantation
15%
Bone Marrow
13%
Relapse-free Survival
13%
Oncology
13%
Non-relapse Mortality
12%
Blood or Marrow Transplantation
11%
Progression-free Survival
11%
Severe Aplastic Anemia
10%
Bone Marrow Transplantation
10%
Myeloablative
10%
Peripheral Blood
9%
Myeloablative Conditioning
9%
Allogeneic Transplantation
9%
Hematological Malignancies
9%
Interferon-α (IFN-α)
9%
Granulocyte Colony-stimulating Factor (G-CSF)
9%
Cyclophosphamide
9%
Cumulative Incidence
8%
Myeloma Cells
8%
Busulfan
8%
Donor Lymphocyte Infusion
8%
Phase II Trial
8%
Allograft
7%
High-dose Cyclophosphamide
7%
Hazard Ratio
7%
Immunosuppression
7%
Acute Lymphoblastic Leukemia
7%
T Cell Depletion
7%
Waldenström Macroglobulinemia
7%
Light Chain Amyloidosis
7%
Lenalidomide
7%
Relapsed or Refractory multiple Myeloma
7%
Older Adults
7%
Cancer Stem Cells
7%
Lymphoplasmacytic Lymphoma
7%
Clinical Practice Guidelines
7%
Medicine and Dentistry
Multiple Myeloma
73%
Cyclophosphamide
54%
Graft Versus Host Reaction
46%
Disease
31%
Drug Megadose
24%
Prophylaxis
21%
Transplantation
21%
Overall Survival
21%
Bone Marrow Transplantation
19%
T Cell
15%
Progression Free Survival
15%
Myeloma
15%
Cancer Stem Cell
14%
Nonmyeloablative Conditioning
13%
Malignant Neoplasm
13%
Oncology
13%
Cumulative Incidence
13%
Allogenic Bone Marrow Transplantation
11%
Lenalidomide
10%
Clinical Trial
10%
Graft Failure
10%
Acute Myeloid Leukemia
9%
Chronic Graft Versus Host Disease
9%
Hematologic Malignancy
9%
Whole Body Radiation
8%
Donor Lymphocyte Infusion
8%
Neoplasm
8%
Recurrence Free Survival
8%
Haploidentical Transplantation
7%
Granulocyte Macrophage Colony Stimulating Factor
7%
Immunosuppressive Treatment
7%
Acute Graft Versus Host Disease
7%
Light Chain
7%
Acute Lymphoblastic Leukemia
7%
Radiation Therapy
7%
Waldenström's Macroglobulinemia
7%
Quality of Life
6%
Allograft
5%
Infection
5%
Combination Therapy
5%
Clinical Research
5%
Lymphocyte
5%
Hazard Ratio
5%
Allotransplantation
5%